Annals of internal medicine
October 6, 2026 · via Europe PMC
In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk.
Airy M, Winkelmayer WC
AI summary — for doctors, generated from the abstract only
Obinutuzumab was more likely than tacrolimus to produce complete remission in primary membranous nephropathy at 104 weeks.
What was studied
A comparison of the anti-CD20 antibody obinutuzumab against tacrolimus in adults with primary membranous nephropathy, with complete remission assessed at 104 weeks.
Key findings
- Obinutuzumab raised the likelihood of complete remission compared with tacrolimus
- Outcome was measured at 104 weeks, a longer horizon than many nephrology trials
Clinical relevance
Nephrologists and generalists managing membranous nephropathy now have evidence favouring a B-cell-depleting agent over a calcineurin inhibitor for achieving durable remission.
Who should care
Limitations
Only the title was available (the abstract text was blank), so sample size, effect size, safety and trial design could not be assessed.
Consider anti-CD20 therapy such as obinutuzumab as a leading option when choosing immunosuppression for primary membranous nephropathy, pending full trial details.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
GIM/FP/GP: [Formula: see text] Nephrology: [Formula: see text].
DOI
10.7326/ANNALS-26-03622-JC
PMID
42832810
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed